Logista Integral, S.A. (CDNIF)
Market Open
10 Aug, 20:00
$
34. 17
0
0%
$
4.51B Market Cap
104.2 P/E Ratio
5.2% Div Yield
194 Volume
6.64 Eps
$ 34.17
Previous Close Want to track CDNIF and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
CDNIF trading today higher at $34.17, an increase of 0% from yesterday's close, completing a monthly increase of 0% or $0. Over the past 12 months, CDNIF stock gained 7.1832%.
CDNIF pays dividends to its shareholders, with the most recent payment made on Feb 26, 2026. The next estimated payment will be in In 2 weeks on Aug 26, 2026 for a total of $1.45888.
The last earnings report, released on Apr 30, 2026, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on 9 different exchanges and in various currencies, with the primary listing on XMAD (EUR).
CDNIF Chart
People also search for
Logista Integral, S.A. (CDNIF) FAQ
What is the stock price today?
The current price is $34.17.
On which exchange is it traded?
Logista Integral, S.A. is listed on OTC PINK.
What is its stock symbol?
The ticker symbol is CDNIF.
Does it pay dividends? What is the current yield?
Yes, It pays dividends and the current yield is 5.2%.
What is its market cap?
As of today, the market cap is 4.51B.
Has Logista Integral, S.A. ever had a stock split?
No, there has never been a stock split.
Logista Integral, S.A. Profile
| Pharmaceuticals Industry | Healthcare Sector | Mr. David A. Ricks CEO | OTC PINK Exchange | ES0105027009 ISIN |
| United States Country | 47,000 Employees | 24 Feb 2026 Last Dividend | - Last Split | 13 Jan 1978 IPO Date |
Overview
Eli Lilly and Company is a global leader in the pharmaceutical industry, focusing on discovering, developing, and marketing human pharmaceuticals. With a broad portfolio of products, the company addresses a wide range of health conditions, from diabetes and oncology to neurologic disorders and autoimmune diseases. Founded in 1876, its headquarters are situated in Indianapolis, Indiana. Eli Lilly and Company maintains a strong commitment to improving patient care and outcomes through collaboration with various partners, including Incyte Corporation, Boehringer Ingelheim Pharmaceuticals, Inc., F. Hoffmann-La Roche Ltd, Genentech, Inc., Biologics, Inc., AbCellera Biologics Inc., and Chugai Pharmaceutical Co., Ltd.
Products and Services
- Diabetes Management
- Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500: A comprehensive range of insulin and insulin analog formulations for the treatment of diabetes.
- Jardiance, Mounjaro, and Trulicity: Oral medications for managing type 2 diabetes.
- Oncology
- Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio: Targeted therapies and chemotherapies for various types of cancer.
- Obesity
- Zepbound: A medication indicated for the treatment of obesity.
- Rheumatology, Dermatology, and Other Conditions
- Olumiant: Used for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19.
- Taltz: For treating plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis.
- Omvoh: A medication for ulcerative colitis.
- Cymbalta: Treats depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain.
- Ebglyss: For severe atopic dermatitis.
- Emgality: Used for the prevention of migraine and the treatment of episodic cluster headaches.
- Other Products
- Cialis: For the treatment of erectile dysfunction and benign prostatic hyperplasia.
- Forteo: An osteoporosis treatment.
Contact Information
Address: Lilly Corporate Center
Phone: 317 276 2000
Website: https://www.lilly.com
